George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines,...
Disability
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
SAN FRANCISCO, April 25, 2024 /PRNewswire/ -- Freedom Biosciences, Inc. ("Freedom Bio" or the "Company"), a clinical-stage biotechnology platform focused on...
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months...
Lifeward Announces the Appointment of Mike Swinford to its Board of Directors
Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business developmentMARLBOROUGH, Mass....
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA)...
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2...
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing...
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone...
Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton
Finalized Medicare reimbursement pathway for personal exoskeletons expands access for all eligible Medicare beneficiariesMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April...
Joint Statement Applauding Final Rule for Web Accessibility Under Title II of the ADA
WASHINGTON, April 10, 2024 (GLOBE NEWSWIRE) -- The American Council of the Blind (ACB), the American Foundation for the Blind...
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Enrollment to continue to the end of April to accommodate strong patient and site interestNAARDEN, the Netherlands and MIAMI, April...
Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry
The ‘My Mental Health Journey’ registry is now enrolling U.S.-based adults experiencing symptoms of depression. The Otsuka-sponsored registry study is...
Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI's single dose Lassa fever vaccine candidateKey takeaways:Participants in...
BioCorRx Reports Business Update for 2023
ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
HCA Healthcare Releases 2024 Annual Impact Report
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced the release of its annual...
Theralase(R) Release’s 4Q2023 Interim Financial Statements
TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Tenon(R) Medical Announces Positive Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran(R) SI Joint Fusion System
Preliminary SI Joint Fusion Results Based on Independent Radiologist Review Indicate Robust Fusion at 12-Months Post-ProcedureInitial Patient Results Demonstrate Marked...